Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

Mrinal Gounder; Albiruni R. Abdul Razak; Adrienne M. Gilligan; Hoyee Leong; Xiwen Ma; Neeta Somaiah; Sant P. Chawla; Javier Martin-Broto; Giovanni Grignani; Scott M. Schuetze; Bruno Vincenzi; Andrew J. Wagner; Bartosz Chmielowski; Robin L. Jones; Jatin Shah; Sharon Shacham; Michael Kauffman; Richard F. Riedel; Steven Attia

doi:10.2217/fon-2021-0284

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

Mrinal Gounder, Albiruni R. Abdul Razak, Adrienne M. Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Jatin Shah, Sharon Shacham, Michael Kauffman, Richard F. Riedel, Steven Attia

Sarcoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials and methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.

Original language	English (US)
Pages (from-to)	2923-2939
Number of pages	17
Journal	Future Oncology
Volume	17
Issue number	22
DOIs	https://doi.org/10.2217/fon-2021-0284
State	Published - Aug 2021

Keywords

advanced liposarcoma
pain
patient-reported outcomes
progression-free survival
quality of life
selective inhibitor of nuclear export
selinexor

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2021-0284

Cite this

Gounder, M., Abdul Razak, A. R., Gilligan, A. M., Leong, H., Ma, X., Somaiah, N., Chawla, S. P., Martin-Broto, J., Grignani, G., Schuetze, S. M., Vincenzi, B., Wagner, A. J., Chmielowski, B., Jones, R. L., Shah, J., Shacham, S., Kauffman, M., Riedel, R. F., & Attia, S. (2021). Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncology, 17(22), 2923-2939. https://doi.org/10.2217/fon-2021-0284

Gounder, M, Abdul Razak, AR, Gilligan, AM, Leong, H, Ma, X, Somaiah, N, Chawla, SP, Martin-Broto, J, Grignani, G, Schuetze, SM, Vincenzi, B, Wagner, AJ, Chmielowski, B, Jones, RL, Shah, J, Shacham, S, Kauffman, M, Riedel, RF & Attia, S 2021, 'Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma', Future Oncology, vol. 17, no. 22, pp. 2923-2939. https://doi.org/10.2217/fon-2021-0284

@article{8dabe026ec59425ba8479635e323a29f,

title = "Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma",

abstract = "Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials and methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.",

keywords = "advanced liposarcoma, pain, patient-reported outcomes, progression-free survival, quality of life, selective inhibitor of nuclear export, selinexor",

author = "Mrinal Gounder and {Abdul Razak}, {Albiruni R.} and Gilligan, {Adrienne M.} and Hoyee Leong and Xiwen Ma and Neeta Somaiah and Chawla, {Sant P.} and Javier Martin-Broto and Giovanni Grignani and Schuetze, {Scott M.} and Bruno Vincenzi and Wagner, {Andrew J.} and Bartosz Chmielowski and Jones, {Robin L.} and Jatin Shah and Sharon Shacham and Michael Kauffman and Riedel, {Richard F.} and Steven Attia",

note = "Publisher Copyright: {\textcopyright} 2021 Karyopharm Therapeutics.",

year = "2021",

month = aug,

doi = "10.2217/fon-2021-0284",

language = "English (US)",

volume = "17",

pages = "2923--2939",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "22",

}

TY - JOUR

T1 - Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

AU - Gounder, Mrinal

AU - Abdul Razak, Albiruni R.

AU - Gilligan, Adrienne M.

AU - Leong, Hoyee

AU - Ma, Xiwen

AU - Somaiah, Neeta

AU - Chawla, Sant P.

AU - Martin-Broto, Javier

AU - Grignani, Giovanni

AU - Schuetze, Scott M.

AU - Vincenzi, Bruno

AU - Wagner, Andrew J.

AU - Chmielowski, Bartosz

AU - Jones, Robin L.

AU - Shah, Jatin

AU - Shacham, Sharon

AU - Kauffman, Michael

AU - Riedel, Richard F.

AU - Attia, Steven

PY - 2021/8

Y1 - 2021/8

N2 - Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials and methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.

AB - Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials and methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.

KW - advanced liposarcoma

KW - pain

KW - patient-reported outcomes

KW - progression-free survival

KW - quality of life

KW - selective inhibitor of nuclear export

KW - selinexor

UR - http://www.scopus.com/inward/record.url?scp=85111024051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111024051&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0284

DO - 10.2217/fon-2021-0284

M3 - Article

C2 - 33855868

AN - SCOPUS:85111024051

SN - 1479-6694

VL - 17

SP - 2923

EP - 2939

JO - Future Oncology

JF - Future Oncology

IS - 22

ER -

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this